Opin­ion: How the FDA bent its rules for Bio­gen’s Alzheimer’s drug and why that’s bad for the en­tire bio­phar­ma ...

5 years ago
FDA+
Opinion

#AS­CO21: As­traZeneca takes a swing at J&J and Ab­b­Vie's Im­bru­vi­ca with long-term da­ta from head-to-head tri­al

5 years ago
R&D

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

5 years ago
R&D
Pharma

Covid-19 roundup: Mod­er­na gets the OK to use vac­cine in chil­dren ages 12-17; 23andMe finds ge­net­ic link to loss of ...

5 years ago
Coronavirus

Spring­Works and Seagen team up in mul­ti­ple myelo­ma; Mer­ck and Ei­sai build out Keytru­da/Lenvi­ma da­ta

5 years ago
News Briefing

From pro­tein degra­da­tion to 'toad ven­om': An­oth­er five biotechs will make the Nas­daq shuf­fle af­ter fil­ing SEC ...

5 years ago
Financing

Der­ma­vant en­gi­neers $160M deal to pay off Glax­o­SmithK­line mile­stones, gear up to launch pso­ri­a­sis cream

5 years ago
Financing

FDA lets blue­bird re­sume tri­als for sick­le cell gene ther­a­py af­ter can­cer scare, but big ques­tions linger over field

5 years ago
R&D

No­vo Nordisk scores a win for semaglu­tide in obe­si­ty, po­ten­tial­ly set­ting up a next-gen bat­tle with Eli Lil­ly

5 years ago
FDA+

A Cell­tri­on-backed biotech is de­vel­op­ing 'tun­able' con­ju­gates to crack sol­id tu­mors — and it has eyes on the clin­ic

5 years ago
Financing

Un­der ‘threat’ of fines, No­var­tis sues HHS over drug pric­ing pro­gram

5 years ago
Pharma

Af­ter a noose was found at NC plant, Mer­ck launch­es in­ter­nal in­ves­ti­ga­tion while de­cry­ing racist acts

5 years ago
Manufacturing

J&J breaks off al­liance with ar­genx, drop­ping CD70 AML drug and ax­ing $1.3B in biobucks

5 years ago
Deals

Glax­o­SmithK­line, As­traZeneca butt heads over li­cens­ing rights to key PARP in­hibitor — re­port

5 years ago
Pharma

As head-to-head with Alex­ion heats up, No­var­tis flash­es da­ta for next wave of tri­als for star kid­ney mol­e­cule

5 years ago
R&D

What ad­u­canum­ab means for Alzheimer's, un­pack­ing a safe­ty bar­ri­er in CAR-T, the push to up­grade a key ALS tri­al tool, ...

5 years ago
Weekly

#AS­CO21: A week af­ter nab­bing pri­or­i­ty re­view, Kite un­veils the piv­otal da­ta it hopes will lead to a new CAR-T ...

5 years ago
R&D

#AS­CO21: Eli Lil­ly-part­nered Merus re­veals new da­ta for NRG1 fu­sion can­cers in­clud­ing pan­cre­at­ic and NSCLC

5 years ago
R&D

What­ev­er the FDA de­cides on ad­u­canum­ab, Alzheimer's re­search is fi­nal­ly, most­ly, kind of mov­ing be­yond the amy­loid ...

5 years ago
R&D
In Focus

Two months af­ter ink­ing a SPAC deal, Ren­o­va­cor taps new CMO; Cure­Vac reels in a new de­vel­op­ment chief from Mer­ck KGaA

5 years ago
Peer Review

Fate sees pos­i­tive B-cell lym­phoma da­ta at #AS­CO21; Imag­inAb se­cures fund­ing for CD8 imag­ing tri­als

5 years ago
News Briefing

Eliz­a­beth War­ren wants Gilead CEO Daniel O'­Day in the hot seat to talk drug pric­ing and com­pet­i­tive­ness

5 years ago
People
Coronavirus

#AS­CO21: As­traZeneca's PD-L1 Imfinzi tacks on 5-year sur­vival da­ta in NSCLC, which it's call­ing 'un­prece­dent­ed'

5 years ago
R&D

Covid-19 roundup: EU calls on WTO mem­bers to ex­pand vac­cine and treat­ment man­u­fac­tur­ing; US re­moves DPA pri­or­i­ty ...

5 years ago
Coronavirus
First page Previous page 693694695696697698699 Next page Last page
A service from the Financial Times